Tag Archives: Alkermes

November, 2018

November, 2017

January, 2016

October, 2015

  • 6 October

    FDA Approves Alkermes’ Schizophrenia Drug

    DUBLIN–(BUSINESS WIRE)–Oct. 5, 2015– Alkermes plc (NASDAQ: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved ARISTADA™ (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia. ARISTADA is the first atypical antipsychotic with once-monthly and six-week dosing options for delivering and maintaining therapeutic levels of medication in the body …